Marketing strategies of GMP syndrome（GMP綜合癥的營銷對策）

1/1MarketingstrategiesofGMPsyndrome（GMP綜合癥的營銷對策）MarketingstrategiesofGMPsyndrome（GMP綜合癥的營銷對策）AccordingtotherelevantdepartmentsofSFDAstatistics,beforeJuly1st,throughtheGMPcertificationofpharmaceuticalenterprisesinabout3100,accountingfor60%ofthecountry.Thereare2000enterprises,nearly900workshopswereforcedtostopproduction.EnterprisesthathavepassedGMPaccountfor90%ofthedomesticpharmaceuticalmarket,andthedrugscoverallthecommonlyusedclinicalproducts,whichcancompletelymeetthemarketdemand.Thereisasayingintheindustry:butGMPGMPisdead,too!Infact,GMPisnotanadministrativetypeofdeathlaw;theimplementationofGMPisaneconomictypeofdeath.ButtherewaslittlenewsornewsthataroundanumberofsmallandmediumenterprisestoabandonGMPcertificationinJuly1staftertheclimaxcontinued,issaidbyGMPtoreducetherepeatedlowleveloftheoriginalbuildingislost!However,smallandmedium-sizedpharmaceuticalcompanieshavepassedthenationalGMPcertification,butitisdifficulttoberecognizedbythemarket,generallysufferingfromGMPsyndrome,thefollowingauthoronthisissue,talkabouttheirownthinkingandcountermeasures.Oneofthesymptoms,operatingcostssubstantiallyimproved1,thecostofimprovingtheclinicalperformance(1)thecostofpassingGMPisprohibitiveItisunderstoodthatGMPhasmorethan80certificationrules,includingmorethan200inspectionitemsetc.druglabelsandinstructionsforuse,ordrug,involvesmanyaspectsofsoftwareandhardware,managementcontent,theimplementationofGMPisacomplicatedandhugesystemengineering.Accordingtopublicinformation,onlythetransformationofafactory,enterprisesspendlessthantheamountofmillionsoffunds,morethantensofmillionsofdegrees.AccordingtothesurveyresearchcenterChinasocialeconomicsurveyinconjunctionwithrelevantassociationsChinapharmaceuticalenterprisecompetitivenessresearchgroupinSichuan,anareaofatotalof21pharmaceuticalcompanies,fixedassetsof1.8million,totalinvestmentandthetransformationofGMP5companiesis220millionyuan.Theannualoutputvalueofanenterpriseisonly10millionyuan,thescientificresearchstrengthisveryweak,only30varietiesandtheproductionofgenericdrugstomaintain,financing50millionyuanthroughtheGMPcertification,howtomaketheequipmentidle,whatproductionvarieties,hasbecometheproblem;seeingloanmaturity,whilethesalesamountisstagnating,lettheenterpriseresponsibleforpeoplescorchedbytheflames.Xi’anpharmaceuticallimitedliabilitycompanyspent35millionyuanrenovationoftraditionalChinesemedicinepreparationworkshopandpassedtheGMPcertification,theannualproductioncapacityof50millionyuanincreasedtonearlybillionyuan,butbecauseoperatingcostsincreasedby20times,thepressureascanbeimagined.(2)theoperationcosthasbeengreatlyimprovedAllcompanieshavesomeGMPafterincreasedoperationalcosts,theauthorheardenterprisemadeinthegovernmentheldameetingtosolverealbusinessproblems:thegovernmentwillallowustomovebacktothenonGMPworkshopproductionoftheoriginaljoke.Thehighoperatingcostsaremanifestedinthefollowingaspects:#61548:firstofall,theproductioncostshavebeengreatlyimproved:theutilitieshavebeensubstantiallyimproved;forexample,apharmaceuticalcompanyinGuangxihasonlyoneelectricitybillpermonth,anincreaseof10thousandyuanmorethanthatoftheoriginalnonGMPworkshop.GuangdongJiangmensomepharmaceuticalcompaniesthroughtheGMPcertification,productioncoststhantheoriginalincreaseofmorethan30%.Theincreaseinproductioncostswillmakesomeoftheprofitmarginsthatoriginallyreliedonsalesvolumes.?managementcostsincreased:strictlyinaccordancewiththeGMPstandardmanagementoperations,makingmanagementcostssoared,butalsoalotofenterprisesoverwhelmed.?lowproductionefficiency:thecausesofthelowefficiencyofthefollowingmainreasons:theselectionofequipment,equipmentinstallation,nowrongworkershaven’tmasteredthetechnicalparametersoftheequipment,withoutlearningcurve.?newplant,equipmentoperationisnotskilled,theproductsproducedhighrateoffailure.2,tosolvetheprescriptionPrescriptionone,large-scaleproduction,improveefficiencyRapidincreaseofproductionworkersonequipmentproficiency,stopproductionbyagroupofcompetentgettersintheshortterm,tograsptheoperationtechnology,shortenthelearningcurveandreducethecostoflearningcurve.Onlyinthiswaycantherateofdefectiveproductsbereducedassoonaspossible,andtheadvantagesofthenewequipmentwillbebroughtintoplay,Improvetheproductionefficiency,inthefiercemarketcompetitionenvironment,largescaleproduction,andstrictlycontroleverylinkcosts,isundoubtedlytheonlypropercoursetotakeenterprisestowinthecompetitiveadvantageoflowcost.Withthecostofrawmaterialsandvariouscostsdown,thetotalcostisautomaticallyreduced.Thesalespriceis10yuanthesameproduct,ifthecostfromtheoriginal5yuandownto3yuannow,sotheenterprisecannotdevelopnewconsumers,occupynewmarket,butalsofromtheexistingmarketsharetowinmorethantheoriginalsalesprofit.Prescriptiontwo,assoonaspossibletopreventproductionoftechnicalpersonneltotacklekeyissues,shortentheproductionoflearningcurvetimeIntheprocessofproducingaproductmultipletimes,itisobservedthattheamountofresourcesneededtoproduceaunitofproductioncontinuouslydecreasesastheamountofaccumulatedoutputincreases.Thediminishingeffectofinputfactorsandrelatedcostsisthelearningeffect.Withtheincreaseoftheproductionquantityofproductstogetaproductneededtimeandmaterialconsumptiondecreasedduetoaseriesoffactors,thesefactorsinclude:reducingtheworkerstowork,improvetheproficiencyoftheworkingmethodsandprocessimprovement,wasteandrepeatedwork.Thelearningcurve(empiricalcurve)requiresskilledindustrialworkers.Theproductionprocessoperationandautomobiledriving,workersneedlove,sensitivetorepeatedexplorationtomachines,skilled,andmustbeintheactualoperationtoberipeinstudents,andgraspthecharacteristicsofthemachine.Proficiencyinthemachineisnotashort-termlearningcando,isaneedfortimeexperienceprocess.Manypharmaceuticalcompaniesonlypayattentiontothehardwareinvestment,donotpayattentiontothetrainingofskilledindustrialworkers,theresultscanimprovetheefficiencyandeffectivenessofthenewequipment,newmachines,butnottheadvantage,lowefficiency,oftenwrong,thisisnotthemachinefault,faultmanagementtraining.Irespectfullysuggest,theGMPpharmaceuticalcompanies,aresearchgroup,quicklyestablisheddayandnight,tofindoutthemachineworkingconditions,technicalparametersandoperationrules;masterthekeycontrolpointsofeachprocess,assoonaspossibletoshortenthelearningcurveforthetime,reducetheproductionprocesstimeandrawmaterialconsumptioncost.Prescriptionthree:lookingforfast,highvolume,sharpmarketingmodelssuchasterminalintercept,conferencemarketing,urbanandruralpromotion.Lookingforagents,etc..Toreducetheamountofmoneyneededforsale.Symptomsoftwo:idlecapacity(1)clinicalmanifestation;InShanghai,GuangdongandotherplaceshavepassedGMPcertification,theoutputvalueofenterprisesevenaccountedformorethan90%ofthecity’stotaldrugproduction.ChinaPharmaceuticalEnterpriseManagementAssociationexecutivepresidentYuMingdethink,afterGMPcertification,China’spharmaceuticalindustryovercapacityoverallsituationwillaggravate.ItisunderstoodthatalmostallpharmaceuticalenterprisesintheGMPtransformation,havevaryingdegreesofexpansion.Manyenterpriseshavetheideathatitisdifficulttoborrowfunds,butalsotobuildtheworkshop,butalsotobuyequipment,whynotbuildmorethanoneproductionline?ThisidealeadstoasubstantialincreaseintheproductioncapacityofenterprisesaftertheGMPtransformation.SuchasMaoxianggroup’sacquisitionofMeihePharmaceuticalCo.Ltd.afteraGMPproject,atotalinvestmentof95million895thousandyuan,aftertheformationofextractionof500tons,100millioncapsules,500milliontablets,pills,oralliquidproductioncapacityof100million.CentralPharmaceuticaltransformationofTianjinlasted3yearsuntilcompletion,thetotalinvestmentof60millionyuan,theproductioncapacityincreasesgreatlythaninthepast.StatisticaldatafromtheBeijingconpartpharmaceuticaleconomicandtechnologyresearchcenter,throughtheGMPcertificationofenterprises,about65%oftheproductionlineputenough;morethan50%businessownersinnewvarietiesaround.(2)diagnosisandtreatmentprescription:OEMgenerationprocessing,digestion,idlecapacity.ThedirectoroftheSFDAwhiteboardsaidthattheproductionofdrugsbyentrustmentwascommoninforeigncountriesandthatsocialresourcescouldberationallyused.TherevisedDrugAdministrationLawofChinaalsomadeaclearprovisionforthis.Onthisquestion,ShouldalsobeinlinewithChina’snationalconditions,andgraduallystepclosertointernationalpractice.Atpresent,wemustimplementtheissuedlawsandregulationstoensurethesmoothproductionofpharmaceuticalentrustedproduction.Prescription1:crosscombinationOEM:Enterprisescanactivelyseektocooperatewithsomelargepharmaceuticalenterprises,andbecometheirproductionworkshop,andearnproductionprofits.Becauseofnonewproductfollow-up,SMEsfacedifficultiesinstartingGMP.CanNorthSouthcooperationandNorthSouthenterprisestohelpenterprisescommissionedprocessing,SouthNorthenterprisestohelpenterprisesOEM,orsomethingcooperation,sowewillgreatlyreducethecostoftransportation,especiallyforthesaleofsmallradiusofheavywater,whichissuitabletogranules.Prescriptiontwo:verticaljointOEM:solvingtheOEMimpulseofcirculationenterprisesInfact,drugentrustedprocessinghasbeeninexistenceforalongtime,andpharmaceuticaldistributionenterprisesorpharmaceuticalmarketingpersonnelhaveentrustedthemanufactureofpharmaceuticalcompaniestoaccountforthelargestproportionofentrustedprocessing.MainlyengagedinpharmaceuticalbusinessinShenzhenKangFuIndustrialCompanyChairmanTangWeimingtoldreporters:inthepastsomeofthedrugsbyprocessingmoresubtle,suchastheSouthernChinacoastalareahasbeeninasneakywayforHongkongpharmaceuticalproducts,donotgothroughanyformalities.WiththestandardizationofthepharmaceuticalindustryandtheincreaseofidlerateofpharmaceuticalequipmentafterGMP,thepharmaceuticalprocessingbusinesswillbemoreheated,andtheupwardenthusiasmofthecirculationcompanieswillcontinuetorise.IknowapharmaceuticaldealerinSichuan,expressedhisdesiretodevelopdrugs,sothatmanufacturersOEMOEM.Themedicinecirculationenterprisedynamicofdrugsalesmarketandfuturetrendsareabletobettergraspandknowwhatproductscanbringprofitfortheenterprise,butoftentofindsuchproductsandspendenormousenergy,butalsototheexclusivemanufacturerZhunzixclassofdrugsetc.Farmar,improveproductfactoryprice,pressagentprofit,sothatagentsindifficultposition.Asaresult,theyareeagertodevelopproductswiththeirownintellectualpropertyrights.ButbecausetheyhavenoGMPworkshop,theycannotproject,whichbringsopportunitiesforpharmaceuticalenterprises.Itisentirelypossibletoworkwiththeseenterprisestodevelopproductsfortheirexclusiveproduction.Prescriptionthree:OEMforforeignpharmaceuticalcompaniesHere,specialattentiontodomesticpharmaceuticalcompaniestopayattentiontoandforeignpharmaceuticalgiantmultinationalcorporation,foritsOEM.CheaplaborChineseandrelativelycheapproductioncosts,candodrugsforforeignpharmaceuticalcompaniesinChinaoutsourcingproduction,buttheproductionprocesstheoriginalChinesepharmaceuticalbackwardandunstableproductqualitygreatlyhindersthepatternofahMPcertificationforaccountedforforeignpharmaceuticalcompaniesinChineseproductionoutsourcingcleaningobstacle.JiangsuandZhejiangprovincesofthepharmaceuticalcompanieshavebeguntotrythis,suchastheUnitedStatesZhejiangHisunMerck,SuzhouLidaforWyethpharmaceuticalprocessingandsoon.Globalwell-knownpharmaceuticalenterpriseshaveallenteredChina,Ibelievethisshouldbealargermarket.October13,2004,wasthefirstmajorpharmaceuticalcompaniesoftheFarEastShanghaiXinyipharmaceuticalsofficiallyannounced,thefactoryhasbeenestablishedthefirstFDAwiththeUnitedStatesandtheEuropeanUnionCGMPstandardsolidpreparationproductionbaseofourcountrystate-ownedpharmaceuticalenterprises,thetotalinvestmentwillreach200millionyuan.Theproductionbasedesignannualproductionof5billiongrain,inadditiontotheproductionofXinyiitselflistedEuropeanmarketdrugs,butalsolistedEuropeanmarketofpharmaceuticalOEMproduction.Prescriptionfour:rapidimitationofexpiredtraditionalChinesemedicineprotectionvarieties,andpatentexpiredvarieties,orrapiddevelopmentofhealthfood,digestionandproductioncapacityRDconstraints,genericdrugsarestilldominant.China’spharmaceuticalmarkethasbeendominatedbygenericdrugsforalongtime.Asaresultofinstitutionalreasons,long-termRDfundsareseriouslyinadequateanddonotpayattentiontoRD,sothatenterprisesdonothavenewproducts,thereisnosustainabledevelopmentcapacity.PharmaceuticalcompaniesareexemptfromGMPcertification,andbecauseofthelargeamountofmoneybeingdepositedonGMPprojects,andmostlyloans,thereisnomoremoneyforresearchanddevelopment.Butcapacityisreallymagnified,sogenericsremaindominantforalongtimetocome.Lowlevelimitationandpricewarwillstillbethemainstreamphenomenoninthemarket.About60%ofSMEsinvaryingdegreestowithstandnewresearchanddevelopment,bankloans,marketingchannelconstruction,lackoffundsenormouspressure.Thismakestheenterprisesurgentlyneedtoseebenefitsintheshortestpossibletime,suggesttotakesometechnicalcontentisshort,flat,fastlowprojecttotrytoimitatetheprotectionoftraditionalChinesemedicineaspressingdanger,goodmarketprospectsduetovarieties,varietiesofpatentexpiration.Anotherideaistodeveloporbuyhealthfoodassoonaspossible,tostarthealthfoodproduction,healthfooddevelopmentcycleisshort,lessinvestment,itcanberegardedasagoodrecipefordigestivecapacity.Threeofthesymptoms,theproductproductioncostsincreased,pricesincreased,competitivenessdeclined1,symptoms:smallscale,poorbenefits,competitivedeclineThepresentsituationofourcountry’sdrugisaccountedfor70%ofthemarketforgenericdrugs,profitsaccountedforonly30%;andthemarketshareof30%ofthedrug,itsprofitisashighas70%,throughtheGMPcertification,drugpriceswillbehigher,becausedepreciationthroughGMPisfarlessthanitsprofits.Thereisnoprofitbecauseofgenericdrugs,genericdrugsarelessprofitable,cannotcompensatefordepreciationandinterestonloans.Fromthesmallandmedium-sizedenterprisesprofitlevel,theoriginalmarketcompetitionhasbeenveryintense,andhasintensified,somerelyonpricewarandwinthetemporaryinterestsofthesmallandmedium-sizedpharmaceuticalenterprises,afterGMPcertification,withtheincreaseofrawmaterialcostsandoverallcosts,increasedoperatingcosts,butalsomakesitsownthepriceadvantageofthemomentcometonothing.Inmarketcompetition,facingthehighcost,smallandmedium-sizedpharmaceuticalenterpriseswillbeforcedbyreducingtheirprofitratiotogainnewadvantages,inordertousethepriceofweaponsandcompetitorsrushtoahigherlevel.Inthisway,moreandmoresmallandmedium-sizedpharmaceuticalenterprisesareenteringunprofitablestatus.Thecompetitivenessofsmallandmedium-sizedpharmaceuticalenterpriseshasbeenfurtherweakened.2,tosolvetheprescriptionTheauthorputsforwardthefollowingcountermeasures:Prescription1:abandonthefollowingzeroprofitproductproduction,selectpotentialandprofitableproducts,focusonlarge-scale!Notafraidofsomeproductionlineshutdown.#61548specializesinproducingindividualvarietiesdirectlyforseverallargepharmaceuticallogisticscompaniesThisisdifferentfromOEM,buttheirproductsspecificallyforseverallargelogisticscompanytodo,inordertoreducetheintermediatelinkagent,theformationofdirectsupplypriceadvantage,increasethelargelogisticscompany’spurchasequantityandpurchasefrequency,reducethesalesprocessmanagementfees,andquicklyexpandthemarket.Ifyourmarketingeffortsandmarketingnetworkcoveragetotheseplaces,andthereisthebestnetworkoflargepharmaceuticallogisticsenterprisessuchasHunanKyushu,SichuanKelunmedicinetrade,WuhanXinlong,ShandongWeifangHaiwang,HunanShuanghepharmaceutical,dhi.Dependingonthestronglogisticscapabilitiesofthesecompanies,yourproductscanalsomoverapidlytothewholecountry.Symptomsfour:lackofliquidityClinicalmanifestations:capitaldepositedintheplantequipment,theflowoffundscut!Itisunderstoodthatasmallandmedium-sizedpharmaceuticalenterprisestoimplementGMPtransformationrequiresfundsrangingfrom6millionto40millionyuan,GMPtransformationprocess,orafterthecompletionoftheheavyburdenonthebackoftheburden.Amistersaid:GMPwouldincreaseenterprise’soperationcost,ifcertifiedthelackoffundforscientificresearch,talent,managementandmarketing,enterprisesaredifficulttoparticipateinmarketcompetitiontosurviveinthesameindustry.Almostallofthesmallandmedium-sizedenterprisesaretheuseofthefundsintheGMPtransformation,andthemajorityofbankloans,capitalprecipitationbecomealotofequipmentplant,didnotputintoopenupthemarket,nottomentionthemarketinginvestment!Oneofthesolutionprescriptions:theoverallsaleAsawhole,thefasteryousell,themoreyoucansellit.Reportedly,Manydomesticsmallandmedium-sizedpharmaceuticalcompaniesareactivelyseekingawayout.LikeXi’anthousandsofWoPharmaceuticalCo.,Ltd.,iscurrentlywithaBritishcompanytodiscussthecommissioningoftheprocessing,inordertosolvetheproblemofinadequateconstruction.Recently,theJapanesemarkettoopenthedoor,aprovisionforoverseasenterprisesforJapanesedomesticpharmaceuticalcompaniesOEM(OEM)drugs,nearJapanChinawillTheearlybirdcatches.InsiderspredictthatOEMmaypromotethepharmaceuticalindustrythereisanewbusinessmodel,notonlycansaveanumberofenterprisesunabletopassGMPcertification,butalsocanmakefulluseofidleequipment.Twooftheprescription:borrowmoneyfromthemarketFirst,throughlarge-scaleinvestment,theuseofdealers,agentsfunds.Twoistonegotiatedirectlywiththeoriginalagent,throughthesaleofpartofthesharesoffinancing.Theformationofrisksharingmechanism,sothatagentsanddistributorswillworkhardtopromoteyourproducts.Resolutionthree:jointrestructuringBecausesomelong-termcannotmeettheexcessproductioncapacity,thereisnonewproductdevelopmentlisted,theoriginalvarietyprofitlevel,theoveralloperatingcostsincrease,willinevitablyleadtosomeenterprisesintotheoperatingdifficultiesandbankruptcy,bankruptcy.Therefore,inthenextfewyears,theacquisitionandreorganizationofthepharmaceuticalindustrywillsetoffanewupsurgeandbecomeahottopicofdiscussion.Andthosewithlargestrengthoflargepharmaceuticalenterprisesorgroups,becauseofitsmanyresourcesandcapitaladvantages,willbecomeajoint,acquisition,restructuringandbuyersintheeventofthemaincharacters.Withthepassageoftime,thenearfuture,China’spharmaceuticalmarket,itislikelythatasmallnumberof20%ofenterprisesgraspthevastmajorityof80%ofthemarketandresourcesphenomenon.ItisunderstoodthatXi’anhastriedinthisregard.Xi’anhightechZonehadtriedtomajorpharmaceuticalcompaniesinjointzone,jointparticipationinhigh-techVcfirm,setupaXi’anhitechjointPharmaceuticalCo.Ltd.,establishedalargeproductionbaseinaccordancewiththeGMPstandard,tobuildaplatforminthepharmaceuticalenterprises.Eachcompanywilldeliveritsownvarietiestothejointpharmaceuticalproduction,andthepropertyrightsarestillownedbyallenterprises,andtheenterprisescanconcentrateonsalesandRD.Atthattime,morethanadozenenterpriseshadreachedapreliminaryintentiontojointhesoontobeestablishedjointpharmaceuticalcompany,andeventuallyforvariousreasons,theplanfailedtoachieve.Butafterall,itprovidesawayofthinking.HasreceivedGMPcertificationofstate-ownedpharmaceuticalcompaniesafewyearsagoShuanghepharmaceuticalLimitedbyShareLtdintheacquisitionpaceveryquickly,sinceFebruary1997tocompletetheGMPcertification,hasmergedwith22smalldomesticpharmaceuticalcompaniesandpharmaceuticaltradingcompany,includingDouble-Cranemodern,Shuanghehitech,Mudanjiangcompany,JinShuangheShuanghenewcompany(Shanxi),West(BeijingdoublecraneXi’an,Anhui,Hefei),KunshanShuangheshenluShuanghe,Huaiandoublecraneetc..Symptomsfive:GMPafterthesaleofsmallandmediumenterpriseslackoftalentdiseaseClinicalmanifestation：

AftercertificationofGMPera,howtocarryonthemarketingworkisthemostimportantwork,manyenterprisesinthecertificationtocertificationcenter,ignoremarketing,theoriginalmarketingpersonnelwillonlymakethemarketingofgenericdrugs.Thecertificationneedsmarketingrelatedtoallaspectsofthecarefulplanningandmarketingplans,suchasenterprisestrategyformulation;determinethemarketingmodel,portfoliomodel:theenterprisemainproductsandancillaryproductsforthecreationofnewmarketingmodechoice;marketingteam;salesgrowthpoints,marketingfundsrationallytowiththeuseof.Andallthis,firstofall,tochangeideas.Changethebusinessconceptismoreimportantthanmoney,forthedevelopmentofsmallandmedium-sizedpharmaceuticalenterprises,thedemandforfundsisveryurgentanddesire,asthesayinggoes,onecan’tmakebrickswithoutstraw,butthepremiseisone,thereisnoplanningandmanagementabilityofmanagersandoperatorsoftubestrong,whereevenmorefinancialsupport,businessisdifficulttodo.Therefore,weshouldattract,trainandtaptalents,Itistheideathatsmallandmedium-sizedbusinessoperatorsneedtochangefirst.Wemustsetuphigh-quality,highcostpersonnel,infact,isthemostfriendlyconceptoftalent.Prescriptionsolving:Prescription1:buildyourowntalentteamWhatkindofmarketingenterprisestocreateateamwiththeirchoiceoflong-termmarketingstrategyandmarketingmodel,heretheauthorremindsmallpharmaceuticalcompanies,mustadvancetheanalysisofenvironment,determinetheirowndirectionofdevelopment,andthenrecruitmentrelatedpersonneltraining,themostsuitablefortheirownmarketingmodeofthetalentisthemostusefulandcanretaintalent.Nowyoucanconsiderthemarketingmodeisverymuch:System:contract,agency,dealersystem,officesystemcanbeadopted;marketingtacticsmode,winwinterminaladvertisingmethod,localmarketintensivecultivationpractices,helpsales,marketingmethod,promotionconferencemode,cinemasalesmethod,designedtodotheruralmarketetc..Mustbebasedonthemarketingsystemandmarketingdirectmodetomatchtheappropriatemarketingpersonnel.Toreallyretaintalent:whethertheenterprisecanretaintalent,thekeyquestioniswhetherthereisamechanismtoretainpeople.Hereisthekeytotherealityofmarketingtalentandlong-termexpectations,whetherthereisprofit,whetherreasonableattractive.Forexample,peoplewithmarketingopportunitieshaveacareerwithasenseofaccomplishmentandasenseofself-worth.Thereareemployeestockownershipplansfortalent.Prescriptiontwo:withsocialmarketingtalents.Tobespecific,itistomakeuseofprofessionalmarketingcompaniesinthesociety,professionalrecruitmentagencies,orpharmaceuticalcompaniesspecializinginterminalwinningandmarketopening.Becauseofitsmarketingabilityispoor,somesmallandmedium-sizedpharmaceuticalcompaniesortheacquisitionofpharmaceuticalcompaniesafterGMPtransformation,theoriginalmarketingpersonnelordoesnotapply,orquitaftertransformation,manyenterprises,marketingisblank.Ifthefinancialstrengthisnotenough,justputthewholesalesoutsourcing,itmaywellbeagoodchoice,becauseofthesocialdivisionoflabor,themarketinghasbecomeafull-timejob,salesofcybersourceistheregionalmonopoly,enterprisescanusethe.Thekeyistostraightenoutthementality,andearnonlytheprofitsofproduction.Prescriptionthree:vigorouslyexpandoverseasmarketsChinapharmaceuticalindustryGMPcertification,adawnbringstotheoverseasmarketChinesepharmaceuticalenterprises,especiallypharmaceuticalenterprises,bothlargeandsmallpharmaceuticalenterpriseswillfacethecompetitiononthesameplatform,themarketingworkofthedomesticmarketrelativelyeasier,weonlyneedtopayattentiontoasmal